in oxford england founder dr. bent jakobsen key people eliot forster ceo ; jonathan knowles chairman ; nicholas cross deputy chairman of the board products cancer drugs treatments using t cell receptor technology website www.immunocore.com immunocore is a privately owned british clinical stage biotechnology company 1 based in oxfordshire which researches and develops cancer treatments using t cell receptors tcrs . contents 1 history 2 scientific background 3 clinical pipeline 3.1 imcgp100 4 corporate governance 5 see also 6 references 7 external links history edit immunocore was founded in 2008 as a spinout of german medigene ag who had acquired former avidex in 2006 which was founded in 1999 as a spinout from the university of oxford by dr bent jakobsen . 2 in july 2013 glaxosmithkline paid 142 million for the rights to pre clinical drugs they had developed which act against several targets that immunocore had been working on . 3 in june 2013 immunocore had entered into a similar deal with genentech which according to the deal would earn immunocore an initiation fee of between 10 million and 20 million for each lead program initiated by genentech and in excess of 300 million in milestone payments for each target programme and significant tiered royalties . 4 in january 2014 medimmune the global biologics research and development arm of astrazeneca announced the next oncology research collaboration and licensing agreement for immunocore who then was eligible to receive an upfront payment of 20 million and up to 300 million in development and commercial milestone payments for each target programme selected as well as significant tiered royalties if these programmes are successful . 5 scientific background edit a schematic representation of the mechanism of action for immtacs tcrs are molecules found on the surface of t lymphocytes or t cells and play various roles in the immune system . tcrs are often cited as aiding in recognising foreign antigens being presented by cells which have been infected by viruses or intracellular bacteria . immunocore has developed a line of biologic medicines by combining engineered cancer recognizing tcrs with immune activating complexes which in theory creates a drug that directs the immune system to kill cancer cells . these drugs are commonly referred to as immune mobilizing monoclonal tcrs against cancer immtacs . 6 clinical pipeline edit imcgp100 edit imcgp100 is an immunotherapy for melanoma . 7 clinical trial results reported april 2015 . 8 corporate governance edit the inaugural chairman of immunocore s board of directors was nicholas cross . 1 in late 2013 jonathan knowles succeeded cross in this position and cross was retained as deputy chairman . 1 knowles had previously served as a non executive director since 2010 . 1 in february 2015 it was published that eliot forster had joined immunocore as chief executive officer ceo . 9 see also edit antibody drug conjugate immunostimulant references edit a b c d slatko joshua december 2013 . bms changes senior management team . people on the move biopharma . med ad news . p. 27 . immunocore . immunocore homepage . immunocore . retrieved 13 august 2013 . gsk taps uk firm for beyond antibodies cancer drug technology . fox news channel . 9 july 2013 . retrieved 9 july 2013 . genentech makes potentially 300m pact for immunocore s immtacs . genetic engineering & biotechnology news . 27 june 2013 . retrieved 23 july 2013 . medimmune and immunocore enter immunotherapy agreement to develop novel cancer therapies . liddy nathaniel 2012 . monoclonal tcr redirected tumor cell killing . nature medicine . 18 980 987 . doi 10.1038 nm .2764 . retrieved 5 august 2013 . study to assess the tolerability of a bispecific targeted biologic imcgp100 in malignant melanoma immunocore announces positive clinical trial data for novel first in class immunotherapy at aacr annual meeting 2015 eliot forster ph.d. . people . genetic engineering & biotechnology news . 35 4 . 15 february 2015 . p. 37 . external links edit official website this article about a company of the uk is a stub . you can help wikipedia by expanding it . v t e retrieved from https en.wikipedia.org w index.php title immunocore & oldid 731513819 categories immunomodulating drugsbiotechnology companies of the united kingdompharmaceutical companies established in 2008united kingdom company stubshidden categories engvarb from september 2013use dmy dates from september 2013all stub articles navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages add links this page was last modified on 25 july 2016 at 20 59 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view